Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS

WESTON, Mass.--(BUSINESSWIRE)-- Biogen Idec (NASDAQ:BIIB - News) will present 58 data sets from the companys multiple sclerosis (MS) clinical portfolio of approved and investigational products at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, October 2-5.

The collection of data being presented at ECTRIMS represents Biogen Idecs industry-leading expertise in MS research and showcases the companys deep understanding of differing patient needs. Through decades of cutting-edge science, Biogen Idec has more experience than any other company in advancing the treatment of this disease, recognising that physicians need therapeutic choices to meet treatment goals.

Biogen Idec is proud to be at the forefront of innovation in MS, which has been made possible through our research and development efforts over the past 30 years, said Douglas E. Williams, Ph.D., executive vice president, Research and Development at Biogen Idec. Our commitment has enabled us to bring a number of therapy options to patients, and we are excited to be presenting data on some promising candidates which have the potential to broaden the treatment spectrum for people living with this chronic, debilitating disease.

Data at ECTRIMS will be presented from across Biogen Idecs portfolio, including:

Approved medicines:

TYSABRI (natalizumab): offers established efficacy that has been proven to reduce relapses and slow disability progression.

TECFIDERA (dimethyl fumarate): an oral treatment for relapsing forms of MS, including relapsing-remitting MS (RRMS), which has been clinically proven to significantly reduce important measures of disease activity with a favorable safety/tolerability profile. TECFIDERA is currently approved in the United States, Canada and Australia.

FAMPYRA (prolonged-release fampridine tablets): the first approved treatment to address the unmet medical need of walking improvement in MS patients, demonstrating efficacy in patients with all MS types. Approved in the European Union.

Investigational medicines:

PLEGRIDYTM (pegylated interferon beta-1a): a potential new molecular entity for relapsing forms of MS in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body. Pegylation offers a less-frequent dosing schedule.

Link:
Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS